[go: up one dir, main page]

AR052938A1 - Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 - Google Patents

Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1

Info

Publication number
AR052938A1
AR052938A1 ARP060100869A ARP060100869A AR052938A1 AR 052938 A1 AR052938 A1 AR 052938A1 AR P060100869 A ARP060100869 A AR P060100869A AR P060100869 A ARP060100869 A AR P060100869A AR 052938 A1 AR052938 A1 AR 052938A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
hydroxy
treatment
halogen atom
Prior art date
Application number
ARP060100869A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR052938A1 publication Critical patent/AR052938A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un compuesto de formula (1), en la que R1 representa alquilo C1-6; R2 representa un átomo de hidrogeno, un átomo de halogeno, un grupo hidroxi, alquilo C1-6, alcoxi C1-6, hidroxi-alquiloC1-6, alcoxiC1-6-alquiloC1-6 o halo-alquiloC1-6; R3 representa un átomo de halogeno, alquilo C1-6, alcoxi C1-6, hidroxi-alcoxiC1-6, alcoxiC1-6-alquiloC1-6, alcoxiC1-6-alcoxiC1-6, haloalquilo C1-6, alquilC1-6-tio, alquilC1-6-sulfinilo, alquilC1-6-sulfonilo, alquilC1-6-NH- o (alquil C1-6)2N-; R4 representa un átomo de halogeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, hidroxi-alcoxiC1-6, alcoxiC1-6-alquiloC1-6, alcoxiC1-6-alcoxiC1-6, alquilC1-6NH-, o (alquil C1-6)2N-; R5 representa un átomo de halogeno, alquilo C1-6, alcoxi C1-6, hidroxi-alcoxiC1-6, alcoxiC1-6-alquiloC1-6, alcoxiC1-6-alcoxiC1-6, haloalquilo C1-6, alquilC1-6-tio, alquilC1-6-sulfinilo, alquilC1-6-sulfonilo, alquilC1-6NH-, (alquil C1-6)2N-, H2N-alcoxiC1-6, alquilC1-6-NH-alcoxiC1-6, (alquil C1-6)2N-alcoxiC1-6, H2N-alcoxiC1-6- alquiloC1-6, alquilC1-6-NH-alcoxiC1-6-alquiloC1-6 o (alquil C1-6)2N-alcoxiC1-6-alquiloC1-6; y *indica un centro quiral; o una sal farmacéuticamente aceptable del mismo o un solvato del mismo. Estos compuestos son utiles para el tratamiento de estados de enfermedad provocados por sobreactivacion del receptor VR1 tal como dolor o similares en mamíferos. Esta presente también provoca una composicion farmacéutica que comprende el compuesto anterior.
ARP060100869A 2005-03-10 2006-03-08 Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 AR052938A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66097805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
AR052938A1 true AR052938A1 (es) 2007-04-11

Family

ID=36297248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100869A AR052938A1 (es) 2005-03-10 2006-03-08 Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1

Country Status (16)

Country Link
US (1) US7566739B2 (es)
EP (1) EP1858865B1 (es)
JP (1) JP4906839B2 (es)
AR (1) AR052938A1 (es)
AT (1) ATE443056T1 (es)
CA (1) CA2600409C (es)
DE (1) DE602006009231D1 (es)
DO (1) DOP2006000060A (es)
ES (1) ES2331153T3 (es)
GT (1) GT200600107A (es)
MX (1) MX2007011105A (es)
NL (1) NL1031335C2 (es)
PE (1) PE20061163A1 (es)
TW (1) TW200700398A (es)
UY (1) UY29412A1 (es)
WO (1) WO2006095263A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
JP5159604B2 (ja) * 2005-03-19 2013-03-06 アモーレパシフィック コーポレイション バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物
WO2007120012A1 (en) * 2006-04-19 2007-10-25 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
KR101619341B1 (ko) 2008-01-28 2016-05-11 (주)아모레퍼시픽 바닐로이드 수용체 길항체로서의 신규 화합물, 이의 이성질체 또는 약제학적으로 허용가능한 염, 및 이를 함유하는 약학 조성물
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2010002209A2 (en) 2008-07-02 2010-01-07 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2593439B1 (en) 2010-07-16 2016-08-17 AbbVie Bahamas Ltd. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EP2593226B1 (en) 2010-07-16 2018-11-14 AbbVie Ireland Unlimited Company Phosphine ligands for catalytic reactions
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
EP3522881A4 (en) * 2016-10-05 2020-05-27 Afecta Pharmaceuticals, Inc. HIGHLY MOBILE GROUP B1 PROTEIN INHIBITORS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810716A (en) 1986-04-11 1989-03-07 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
IL155155A0 (en) 1999-09-17 2003-10-31 Cor Therapeutics Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2001064643A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
JP5001505B2 (ja) * 2000-08-21 2012-08-15 株式會社アモーレパシフィック 新規チオウレア誘導体およびこれを含有する薬学的組成物
KR100453078B1 (ko) * 2000-08-21 2004-10-15 주식회사 태평양 신규 티오우레아 화합물 및 이를 함유하는 약제학적 조성물
JP2005504841A (ja) 2001-10-04 2005-02-17 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
KR100556158B1 (ko) * 2002-10-17 2006-03-06 (주) 디지탈바이오텍 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물
KR100707123B1 (ko) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
US20050085449A1 (en) 2003-10-15 2005-04-21 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
WO2005040093A1 (ja) 2003-10-24 2005-05-06 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物

Also Published As

Publication number Publication date
CA2600409C (en) 2011-07-05
JP2008532994A (ja) 2008-08-21
EP1858865A1 (en) 2007-11-28
US7566739B2 (en) 2009-07-28
US20060205980A1 (en) 2006-09-14
ATE443056T1 (de) 2009-10-15
WO2006095263A8 (en) 2007-11-08
EP1858865B1 (en) 2009-09-16
DOP2006000060A (es) 2006-09-30
MX2007011105A (es) 2007-10-08
ES2331153T3 (es) 2009-12-22
CA2600409A1 (en) 2006-09-14
TW200700398A (en) 2007-01-01
NL1031335C2 (nl) 2007-01-23
JP4906839B2 (ja) 2012-03-28
PE20061163A1 (es) 2006-10-27
WO2006095263A1 (en) 2006-09-14
DE602006009231D1 (de) 2009-10-29
GT200600107A (es) 2006-12-26
NL1031335A1 (nl) 2006-09-12
UY29412A1 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
AR052938A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
AR053344A1 (es) Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
AR064253A1 (es) Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1
AR063211A1 (es) Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide.
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
ATE517882T1 (de) Chinolinderivate
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
UY30407A1 (es) Derivados de [2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-8-il]-fenil sulfonatos sustituidos, composiciones farmacéuticas y aplicaciones.
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
TW200833697A (en) Spiro-piperidine derivatives
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden

Legal Events

Date Code Title Description
FB Suspension of granting procedure